Immunotherapies for Life

Clinical Pipeline Highlights

Product Target Load Indication Development Phase


Phase I

Phase I/II

Phase II

Phase III

Burtomab B7-H3 131l CNS/Leptomeningeal Metastasis from Neuroblastoma (BTD, ODD and RPDD)
Burtomab B7-H3 131l Desmoplastic Small Round Cell Tumor
Burtomab B7-H3 124l Diffuse Intrinsic Pontine Glioma
Burtomab-DOTA B7-H3 177Lu B7-H3 positive LM tumors (Adult)
hu8H9 B7-H3 TBD Solid Tumors (Adult)
Naxitamab GD2 Naked Refractory/Relapsed Neuroblastoma
Naxitamab GD2 Naked Osteosarcoma (Pediatric)
hu3F8-BsAb GD2xCD3 Naked GD2 positive solid tumors (Adult)
hu3F8-BsAb GD2xCD3 Naked Refractory Neuroblastoma and Ewing's Sarcoma (Pediatric)

BTD (Breakthrough Therapy Designation), ODD (Orphan Drug Designation) and RPDD (Rare Pediatric Disease Designation)


Y-mAbs Therapeutics, Inc (YmAbs) is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center (“MSK”) under an exclusive worldwide license and research collaboration agreement. YmAbs applies its world-class antibody capabilities to create life-changing immunotherapies for cancer patients of all ages. YmAbs’ innovative product candidates leverage its extensive drug development capabilities and its proprietary protein technology platform – MULTI TAG™.


YmAbs mission is to discover, develop and deliver novel antibody therapeutics for the treatment of both pediatric and adult cancer patients.

Company Highlights

  • YmAbs is a clinical stage biotechnology company specialized in developing novel antibody therapeutics to treat cancer
  • Memorial Sloan Kettering Cancer Center, the world’s largest and oldest private cancer institution, is YmAbs’ scientific collaboration partner and shareholder
  • From MSK, YmAbs has exclusive global rights to two clinical stage antibody programs with a strong validated clinical safety profile, treating more than 1,000 neuroblastoma patients. These programs are today used as “standard-of-care” treatment for patients at Memorial Sloan Kettering Cancer Center
  • Further, YmAbs has licensed a protein Multimerization Technology Platform – MULTI TAG™, incubated and developed at MSK to further enhance the therapeutic effect of antibodies
  • Several ongoing clinical trials significantly improve survival rates for critical unmet medical needs among cancer patients
  • YmAbs has a management team with proven track record and antibody drug development experience as well as expertise in running leading public biopharmaceutical companies